For research use only. Not for therapeutic Use.
Sulopenem（Cat No.:R034765）is a novel penem antibiotic developed to treat bacterial infections, particularly those caused by drug-resistant Gram-negative and Gram-positive bacteria. It inhibits bacterial cell wall synthesis, making it effective against pathogens responsible for urinary tract infections, respiratory infections, and certain abdominal infections. Sulopenem is available in both intravenous and oral formulations, providing flexibility in treatment options. Its stability against beta-lactamase enzymes and broad-spectrum activity make it a promising solution for addressing antibiotic-resistant infections, with potential to improve patient outcomes in both outpatient and hospital settings.
| Catalog Number | R034765 |
| CAS Number | 120788-07-0 |
| Synonyms | (5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid; (S)-CP 70429; CP 70429; [5R-[3(1R*,3S*),5α,6α(R*)]]-6-(1-hydroxyethyl)-7-oxo-3-[(tetrahydro-1-oxido-3-thienyl |
| Molecular Formula | C₁₂H₁₅NO₅S₃ |
| Purity | ≥95% |
| Target | Beta-lactamase |
| Storage | -20°C |
| IUPAC Name | (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1 |
| InChIKey | FLSUCZWOEMTFAQ-PRBGKLEPSA-N |
| SMILES | C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O |
| Reference | </br>1:Comparative antipneumococcal activities of sulopenem and other drugs. Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.Antimicrob Agents Chemother. 2009 Jun;53(6):2239-47. doi: 10.1128/AAC.01531-08. Epub 2009 Mar 23. PMID: 19307366 Free PMC Article</br>2:Antianaerobic activity of sulopenem compared to six other agents. Ednie LM, Appelbaum PC.Antimicrob Agents Chemother. 2009 May;53(5):2163-70. doi: 10.1128/AAC.01557-08. Epub 2009 Feb 17. PMID: 19223615 Free PMC Article</br>3:Reduction of in-source collision-induced dissociation and thermolysis of sulopenem prodrugs for quantitative liquid chromatography/electrospray ionization mass spectrometric analysis by promoting sodium adduct formation. Wujcik CE, Kadar EP.Rapid Commun Mass Spectrom. 2008 Oct;22(20):3195-206. doi: 10.1002/rcm.3722. PMID: 18803331 </br>4:[In vitro activities of sulopenem, a new parenteral penem, against anaerobes]. Watanabe K, Kato N, Tanaka-Bandoh K, Tanaka Y, Kato H, Ueno K.Jpn J Antibiot. 1996 Apr;49(4):367-76. Japanese. PMID: 8786627 </br>5:[In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic]. Komoto A, Otsuki M, Nishino T.Jpn J Antibiot. 1996 Apr;49(4):352-66. Japanese. Erratum in: Jpn J Antibiot 1996 May;49(5):508. PMID: 8786626 </br>6:[Antibacterial activity of sulopenem, a new parenteral penem antibiotic]. Inoue E, Komoto E, Taniyama Y, Mitsuhashi S.Jpn J Antibiot. 1996 Apr;49(4):338-51. Japanese. PMID: 8786625 </br>7:[In vitro antibacterial activity of a new parenteral penem, sulopenem]. Yoshida T, Tateda E, Hiramatsu K, Yokota T.Jpn J Antibiot. 1996 Apr;49(4):324-37. Japanese. PMID: 8786624 </br>8:[In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins]. Nagashima M, Goto S, Yoshida T, Matsunaga T, Shimohira H, Ogawa M.Jpn J Antibiot. 1996 Apr;49(4):303-23. Japanese. PMID: 8786623 |
